Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view

Hui-Ting Chen, Hong-Li Huang, Yong-Qiang Li, Hao-Ming Xu, Yong-Jian Zhou

Abstract
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent metabolic disorder with steadily increasing incidence rates worldwide, especially in the West. There are no drugs available at present to treat NAFLD, and the primary therapeutic options include weight loss and the combination of healthy diet and exercise. Therefore, novel interventions are required that can target the underlying risk factors. Gut microbiota is an “invisible organ” of the human body and vital for normal metabolism and immuno-modulation. The number and diversity of microbes differ across the gastrointestinal tract from the mouth to the anus, and is most abundant in the intestine. Since dysregulated gut microbiota is an underlying pathological factor of NAFLD, it is a viable therapeutic target that can be modulated by antibiotics, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and microbial metabolites. In this review, we summarize the most recent advances in gut microbiota-targeted therapies against NAFLD in clinical and experimental studies, and critically evaluate novel targets and strategies for treating NAFLD.

Key words: Non-alcoholic fatty liver disease; Gut microbiota; Probiotics; Prebiotics; Fecal microbiota transplantation; Metabolites

Core tip: Non-alcoholic fatty liver disease is a highly prevalent metabolic disease worldwide. In this review, we summarize the most recent advances in gut microbiota-targeted therapies against non-alcoholic fatty liver disease, including antibiotics, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and the gut...
microbiota-derived components and metabolites.

INTRODUCTION

The liver is the largest organ in our body, with vital functions in digestion, energy storage, and detoxification. Fatty liver disease is the most common hepatopathological condition characterized by excessive fat accumulation in the liver. Based on the etiology, fatty liver disease can be classified into the alcoholic and non-alcoholic types. As the name indicates, alcoholic fatty liver disease is the result of alcohol overconsumption. Ethanol metabolism in the liver produces fatty acids which steadily accumulate within the liver cells, along with acetaldehyde and free radicals that also have deleterious effects on the liver and other organs[9]. Non-alcoholic fatty liver disease (NAFLD) is caused by multiple factors including poor diet, insulin resistance, and other metabolic disturbances[6]. In addition, lifestyle-related factors like sleep shortage, irregular food intake, sedentary habits, and excessive weight gain are also risk factors for NAFLD[8]. It can be further sub-divided into the fatty liver without inflammation and nonalcoholic steatohepatitis (NASH) types. The latter frequently progresses to fibrosis, advanced cirrhosis, hepatocellular carcinoma (HCC), and even death[4]. NAFLD is in fact the most rapidly increasing underlying condition requiring liver transplantation[9], and can be considered a hepatic manifestation of the metabolic syndrome. Several clinical trials are underway to develop novel therapies against NAFLD[6], since the current treatments focusing on lifestyle modifications have been largely approved. Mediterranean diet and physical activity for instance have been shown to prevent the onset of NAFLD[6]. The ultimate goal of NAFLD treatment is to inhibit fibrotic development that can eventually lead to cirrhosis and HCC[1]. However, there are no Food and Drug Administration approved drugs at present for treating this condition[9].

The gut microbiota is considered by many as a “metabolic organ” that plays a vital role in host metabolism and liver function[10]. In addition to the classic “two-hit” theory or the updated “multiple hit” model[10], intestinal dysbiosis is also a causative factor of NAFLD, and promotes its progression by modulating host energy metabolism, insulin sensitivity, immune response, and inflammation[11]. The pathophysiological relationship between the gut microbiota and NAFLD is complex and involves diverse immunological and metabolic pathways. For instance, impaired intestinal permeability in mice lacking the junctional adhesion molecule A protein (Jam1) or Muc2 increases the risk of liver inflammation when the animals are fed a high-fat diet (HFD)[12]. Furthermore, the microbiota from adult NAFLD patients exhibits differences in carbon and amino acid metabolism[13]. NAFLD is also associated with increased serum TMAO levels and hepatic bile acid (BA) synthesis[14] and less production of phosphatidylcholine[15]. The pathological roles of various bacterial metabolites and microbiota-generated secondary BA in NAFLD have been unearthed in recent years[16]. These metabolites can trigger metabolic dysfunction and contribute to NAFLD development and progression by targeting relevant pathways. The gut microbiota also diversifies the repertoire of host BAs and participates in host metabolism, insulin sensitivity, immune response, and inflammation[12]. The gut microbiota-targeted therapies against NAFLD in clinical and experimental studies, and critically evaluate novel targets and strategies for treating NAFLD.

Therefore, researchers are increasingly focusing on the gut microbiota as a new therapeutic target for NAFLD, and have developed various treatment modalities including antibiotics, probiotics, prebiotics, symbiotics, fecal microbiota transplantation (FMT), gut microbiota-derived components, and metabolites (Figure 1). In this review, we summarize the most recent advances in gut microbiota-targeted therapies against NAFLD in clinical and experimental studies, and critically evaluate novel targets and strategies for treating NAFLD.
Gut microbiota dysbiosis and impaired intestinal barrier have been elucidated as pathogenic factors in non-alcoholic fatty liver disease. Antibiotics, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and gut microbiota-derived components and metabolites are important treatments targeting the gut microbiota. FMT: Fecal microbiota transplantation.

**ANTIBIOTICS**

Antibiotics can eliminate harmful microbiota, and their efficacy has been confirmed in various liver diseases\(^{[21-27]}\). Since the 1950s\(^{[28,29]}\), neomycin, metronidazole, rifaximin, and polymyxin B have been used extensively for treating cirrhosis and hepatic encephalopathy. In addition, concurrent polymyxin B and neomycin use prevented lipid accumulation in the liver by altering the gut microbiota\(^{[30]}\). Gangarapu \textit{et al.}\(^{[31]}\) found that short-term administration of antibiotics improved the clinical symptoms in NAFLD/NASH patients by lowering circulating endotoxins as well as serum transaminases. Consistent with this, another study\(^{[32]}\) reported a significant reduction in the levels of transaminase and NAFLD-liver fat score after rifaximin treatment. However, in a recent clinical trial conducted by Ponziani \textit{et al.}\(^{[33]}\), rifaximin showed little therapeutic effects against NASH. This discrepancy could be the result of low drug dose, short duration of the treatment, and small sample size. Antibiotic-induced changes in the gut microbiota can provide valuable insights into its therapeutic utility in various diseases. Specific antibiotics can positively affect the gut microbiota by promoting the growth of beneficial gut bacteria like \textit{Bifidobacteria} and \textit{Lactobacilli}. While short-term antibiotic treatment may have a therapeutic effect, long-term application can lead to the emergence of bacterial resistance, thereby limiting the efficacy of the drug and increasing the risk of secondary infections. Therefore, chronic antibiotic use is not encouraged since they can affect the beneficial gut bacteria and cause intestinal dysbiosis\(^{[34]}\).
PROBIOTICS

Probiotics are non-pathogenic microbes that alleviate gut disorders by restoring the normal microbiota, and provide overall health benefits to the host[49]. These beneficial bacteria can reduce lipid deposition, endotoxia, oxidative stress, and inflammation by regulating the expression levels of TNF-α, NF-κB, and collagen[49]. Probiotic strains for therapeutic applications are selected on the basis of safety, functionality, and technical requirements[50]. For instance, some *Streptococcus*, *Lactobacillus*, and *Bifidobacteria* strains can regulate the mucosa-motivated immune system and gastrointestinal inflammation, and promote the growth and survival of gut epithelial cells[49].

Probiotics have shown significant therapeutic effects on the murine fatty liver model as well. Administering probiotics to mice fed an HFD significantly slowed the progression of hepatic steatosis and fibrosis[49]. However, most studies on NAFLD rodent models have been aimed at preventing, rather than treating, diet-induced liver disease[49]. Clinical trials on NAFLD patients have shown that *Lactobacillus*, *Streptococcus*, and *Bifidobacterium* strains play an ameliorative role by restoring the levels of the liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT)[50]. For instance, the intra-hepatic levels of AST and ALT increased significantly in NAFLD patients following 3 mo of treatment with *Lactobacillus bulgaricus* (*L. bulgaricus*) and *Streptococcus thermophilus* (*S. thermophilus*)[54].

**MIYAIRI 588**, a probiotic *Clostridium butyricum* strain originally from Japan and used widely in Asia, prevented fatty degeneration from progressing to liver cancer in a rat NAFLD model[50,54]. In addition, co-administration of several probiotic strains, such as the VSL3 formulation including eight probiotic bacterial strains [ *S. thermophilus*, *Bifidobacterium breve*, *Bifidobacterium longum* (*B. longum*), *Bifidobacterium infantis*, *Lactobacillus casei*, *Lactobacillus plantarum*, *Lactobacillus acidophilus*, and *L. bulgaricus*] resulted in greater therapeutic effects compared to any single strain[52-54]. A randomized controlled trial conducted on overweight children with NAFLD showed significant improvement in the fatty liver condition and BMI following treatment with VSL3. Subsequent studies indicated that the increase in total and active GLP-1 as well as decrease in the plasma levels of S-nitrosothiols, malondialdehyde, and 4-hydroxynonenal was the potential mechanisms underlying the therapeutic effects of VSL3[55,56]. Furthermore, VSL3 can alleviate chronic liver diseases by protecting the intestinal barrier and reducing endotoxemia and oxidative/nitrosative stress[6,46].

However, probiotics are primarily derived from bacteria, which raises concerns of biosafety. A few probiotics derived from yeast (e.g., *Saccharomyces boulardii*) have shown encouraging effects, especially when combined with traditional bacterial probiotics[54]. Further research is needed to optimize the efficacy, safety, and sustainability of probiotics for treating NAFLD.

PREBIOTICS

The International Scientific Association for Probiotics and Prebiotics defines prebiotics as substrates that are broken down by host microorganisms into metabolites[22] that promote the growth of beneficial bacteria[49]. Prebiotic feeding is an effective adjuvant therapy for liver diseases, which improves the symptoms by restoring gut microbiota[10,58]. Oligofructose, a mixture of nondigestible fermentable dietary fiber[19], reduced liver oxidative stress and inflammation by improving intestinal permeability and tight junction integrity. Prebiotics stimulated the growth of *Bifidobacteria* and normalized plasma endotoxin levels, which improved glucose tolerance and subsequently resulted in weight loss in obese individuals[37]. Lactulose is another prebiotic that promotes the growth of *Bifidobacteria*, *Lactobacillus*, and Gram-positive bacteria and inhibits the endotoxemic Gram-negative bacteria[50]. HFD-fed obese mice that were administered lactulose for 6 wk showed reduced inflammation and liver damage, which correlated to decreased circulating levels of lipopolysaccharides[48]. In addition, the fungal prebiotic chitin-glucan can also limit weight gain, glucose intolerance, liver triglyceride accumulation, and fasting hyperglycemia by modulating the gut microbiota[50].

The beneficial effects of prebiotics on NAFLD can be attributed to reduced *de novo* lipogenesis, weight and fat loss, improved blood glucose control, restored gut microbiota, and lower inflammation[46]. Clinical trials have also demonstrated therapeutic effects of prebiotics on NAFLD/NASH progression via modulation of glucose homeostasis and lipid metabolism[57]. In conclusion, prebiotics are a highly suitable therapeutic tool against NAFLD.
SYNBIOTICS

Synbiotics are the combination of probiotics and prebiotics. NASH patients treated with *Bifidobacterium* and fructo-oligosaccharides (FOS) for 6 mo showed significantly lower serum ALT and AST levels compared to the placebo group\(^{[60]}\), indicating the potential advantage of using synbiotics against liver diseases. Another study showed that synbiotic supplementation with seven probiotic strains (*Lactobacillus casei*, *L. bulgaricus*, *Lactobacillus rhamnosus*, *Lactobacillus acidophilus*, *Bifidobacterium breve*, *B. longum*, and *S. thermophilus*) and FOS for 28 wk, along with healthy lifestyle modifications, was more beneficial (in terms of reduced inflammation and BMI) to NAFLD patients compared to lifestyle changes alone\(^{[61]}\). Malaguarnera et al\(^{[62]}\) reported that co-administering *B. longum* and FOS for 24 wk combined with a healthy lifestyle significantly decreased NASH activity index and hepatic fat accumulation. Likewise, Safavi et al\(^{[63]}\) found that long-term synbiotic treatment significantly decreased serum lipid levels in obese children. A meta-analysis of 15 randomized controlled trials including a total of 782 NAFLD patients showed that synbiotics markedly attenuated liver steatosis, ALT, AST, high-density lipoprotein, low-density lipoprotein, triglyceride and cholesterol levels, TNF-α expression, the degree of liver stiffness, and homeostasis model assessment-insulin resistance\(^{[64]}\).

Fecal microbiota transplantation (FMT) involves transferring functional microbiomes from the feces of healthy individuals to the gastrointestinal tract of patients with intestinal dysbiosis. It was introduced by Chinese medical and herbal practitioners for treating severe diarrhea and food poisoning\(^{[65]}\). FMT is an effective therapeutic option for recurrent *Clostridium difficile* infection, as well as liver and metabolic diseases associated with intestinal microbiota dysbiosis. The clinical studies conducted so far on microbiota-targeting strategies, including FMT, in NAFLD patients are summarized in Table 1.

Studies show\(^{[64,65]}\) that transplanting the gut microbiota from lean or obese mice induced phenotypes similar to that of the host, with the microbiota of lean donors significantly reducing adiposity in the obese mice. However, Fischer et al\(^{[66]}\) observed no improvement in the BMI of *Clostridium difficile* infection patients within 12 mo of a single FMT, regardless of the donor BMI. In contrast, overweight patients with metabolic syndrome showed a significant improvement in hepatic (119%) and peripheral (176%) insulin sensitivity 6 wk after receiving microbiota from lean healthy controls compared to the autologous microbiota\(^{[67]}\). Several studies have demonstrated the therapeutic effects of FMT on type 2 diabetes and ulcerative colitis patients\(^{[68-72]}\), which were associated with restored healthy microbiota, normalized blood lipid levels, and improved insulin resistance.

Based on these reports, we can surmise that FMT is a potential therapeutic option for NAFLD and NASH as well. To determine the role of the gut microbiota in NAFLD development, Le Roy et al\(^{[73]}\) transplanted the feces from HFD responder and non-responder mice into germ-free recipients. The mice that received microbiota from the responder group developed steatosis and showed a high abundance of *Barnesiella* and *Roseburia* in the intestine, whereas microbiota from the non-responder mice markedly increased the abundance of *Allobaculum* in the recipients. Furthermore, an 8-wk FMT intervention\(^{[74]}\) significantly restored the disordered gut microbiota in HFD-induced NASH mouse models by increasing the abundance of beneficial bacteria such as *Christensen* and *Lactobacillus*. It also alleviated endotoxemia, liver steatosis, necrosis, and intra-hepatic inflammation compared to the untreated controls. Consistent with this, metabolic syndrome patients transplanted with the gut microbes of healthy individuals showed increased butyrate production and improved insulin sensitivity\(^{[75]}\), which could be attributed to the higher abundance of beneficial bacteria in the lower gut.

Fecal matter can be implanted through nasogastric tubes, nasojejunal stomy tubes, upper gastrointestinal endoscopy (gastroduodenoscopy), colonoscopy, or retention enema, and the outcomes of these methods differ significantly. In addition, the heterogeneity of donor fecal matter also influences the therapeutic effect. FMT is also associated with the risk of unpredictable infections from the transplanted microorganisms under certain circumstances. Finally, the stability of foreign bacteria into the host gut is limited, which can reduce their long-term survival and therapeutical effects\(^{[76]}\). Therefore, further clinical trials are warranted to confirm the therapeutic benefit of this strategy.
Chen HT et al. Microbiota-targeted therapies against NAFLD

Table 1  Clinical trials (centered on phase 2 or phase 3) that target the gut microbiota involved in non-alcoholic fatty liver disease

| NCT number     | Condition(s)          | Intervention | Phase | Status            | Country |
|----------------|-----------------------|--------------|-------|-------------------|---------|
| NCT01355575   | NAFLD                 | Antibiotics  | Phase 4 | Terminated        | United Kingdom |
| NCT0229405    | NAFLD                 | Antibiotics  | Phase 4 | Completed         | Finland |
| NCT0175628    | NAFLD                 | Antibiotics  | Phase 2 | Completed         | Iran    |
| NCT0171271    | NAFLD                 | Antibiotics  | Phase 2 | Completed         | Iran    |
| NCT01654549   | NAFLD                 | Antibiotics  | Phase 2 | Completed         | Iran    |
| NCT01876108   | Fatty liver           | Antibiotics  | Phase 2 | Completed         | Iran    |
| NCT02510599   | NASH                  | Antibiotics  | Phase 2 | Unknown status¹  | Spain   |
| NCT00068094   | Fatty liver           | Probiotics   | Phase 1/Phase 2 | Terminated     | United States |
| NCT02872567   | Metabolic syndrome/NAFLD | Probiotics  | Phase 2 | Unknown status¹  | Spain   |
| NCT03511365   | NAFLD                 | Probiotics   | Phase 1/Phase 2 | Terminated     | United States |
| NCT0385413    | Obesity/NAFLD         | Probiotics   | Phase 3 | Recruiting        | Germany |
| NCT04175932   | Fatty liver disease   | Probiotics   | Phase 1/Phase 2 | Not yet recruiting | United States |
| NCT02530138   | NASH                  | Symbiotics   | Phase 2/Phase 3 | Unknown status¹ | Iran    |
| NCT01791597   | NASH                  | Symbiotics   | Phase 2/Phase 3 | Completed       | Iran    |
| NCT02499390   | Diabetes mellitus/NAFLD | FMT           | Phase 1/Phase 2 | Completed       | Canada  |
| NCT02530385   | Obesity/NAFLD         | FMT          | Phase 1/Phase 2 | Completed       | United States |
| NCT02741518   | Obesity/NAFLD         | FMT          | Phase 1/Phase 2 | Active, not recruiting | United States |
| NCT02970877   | Obesity/NAFLD         | FMT          | Phase 2 | Recruiting        | Canada  |
| NCT02050607   | Metabolic syndrome/NAFLD | FMT           | Phase 3 | Unknown status¹  | Italy   |
| NCT02862249   | Cirrhosis             | FMT          | Phase 3 | Recruiting        | United Kingdom |
| NCT0014505    | Cirrhosis             | FMT          | Phase 1/Phase 2 | Unknown status¹ | China   |

¹Study has passed its completion date and status has not been verified in more than two years. Data from https://clinicaltrials.gov/. FMT: Fecal microbiota transplantation; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis.

GUT MICROBIOTA-DERIVED COMPONENTS AND METABOLITES

Studies[87-94] show that the interaction between gut microbiota and their hosts is mediated by various metabolites that are secreted, degraded, or modified by the former, such as short-chain and long-chain fatty acids, amino acids, bile acids, vitamins, and polysaccharides. These metabolites form an intricate signaling network that affects host metabolism and prevents the growth of pathogenic bacteria, and therefore can be utilized to restore the gut microbiota and supplement the effects of FMT or probiotics[85].

Short chain fatty acids (SCFA) supplementation have shown ameliorative effects in cancer[86-89], metabolic diseases[90-92], and other diseases. SCFA is produced during the fermentation of dietary fiber in the gut, and can activate G protein coupled receptor and lower histone deacetylase activity. It is also a fuel for gut epithelial cells and regulates multiple metabolic pathways in the intestine[93]. SCFA administration in metabolic diseases modulates immune homeostasis, gut hormone secretion, inflammatory response, gut barrier, and other functions[94].

Bile acid (BA) is a cholesterol derivative that is synthesized and conjugated in the liver. It plays a central role in digestion by emulsifying dietary fats and promoting the absorption of lipids and vitamins in the small intestine (mainly the ileum), which affects hepatic lipid accumulation and inflammation. Thus, BA is a critical signaling molecule that functionally connects the intestine and liver. The BA receptor (BAR), also known as FXR, is highly expressed in the liver and intestine and regulates the synthesis of bile acids through a feedback mechanism. A recent study identified TGR5 as another major BAR in the liver[89]. The underlying mechanisms remain to be elucidated in order to determine whether FXR agonistic or antagonistic effects are beneficial to NAFLD. Amino acid catabolites play a regulatory role in NAFLD by influencing intestinal epithelial barrier and have therapeutic effects on liver function[90]. Indole propionic acid and other indole-like molecules maintain the integrity of intestinal epithelial barrier[91] and control inflammation, and can directly act on hepatocytes and liver immune cells[92].

Gut microbiota-derived metabolites can overcome the major disadvantage of colonization resistance associated with probiotics and FMT. However, metabolite
therapy also has several limitations that ought to be considered\(^8\). First, the endogenous gut microbiota and the exogenous metabolites may interact unpredictably, which can aggravate the intestinal dysbiosis or even alter the gut microbiota to produce harmful metabolites. Second, the sudden change in the intestinal levels of the supplemented metabolites may also disrupt the feedback loops of the endogenous metabolites. Long-term supplementation of metabolites can even lead to the emergence of host or bacterial resistance, and thus alter the therapeutic target. Third, the low level of some metabolites in the feces may not truly reflect the status in the intestine, and the suboptimal absorption of oral metabolites in the proximal gastrointestinal tract would decrease their effects on the distal small intestine and colon. In addition, the long-term and systemic effects of these metabolites are unknown and need to be elucidated through detailed pharmakinetics and pharmacodynamics studies. Finally, bacterial metabolites have very complex chemical structures and some are even volatile, which makes laboratory synthesis technically challenging\(^9\). Taken together, the clinical application of bacterial metabolites will have to be supported by strong experimental foundations.

**CONCLUSION**

NAFLD is a common chronic liver disease that can progress to cirrhosis and HCC, and the prevalence of NAFLD/NASH is increasing globally. The advent of high-throughput sequencing has increased the potential for microbiota-targeted NAFLD/NASH treatment. Apart from bacteria, the intestinal microbiome includes fungi, viruses, and archaeabacteria, which are associated with various liver diseases. Therefore, it is logical to target the gut–liver axis, especially the microbiota, in order to alleviate the symptoms of NAFLD. Although conventional antibiotics can modulate NAFLD symptoms, their clinical use is largely limited due to their side effects and the emergence and prevalence of bacterial resistance. Probiotics, prebiotics, and synbiotics are safe and effective alternatives to conventional antibiotics for treating NAFLD. In addition, FMT is also a promising strategy that can reverse the intestinal dysbiosis associated with NAFLD. Novel therapies involving gut microbiota-derived components and metabolites are increasingly being developed for their unique advantages. The next generation microbiota-targeted therapies against NAFLD include genetically engineered microbiota and recombinant metabolites. Furthermore, the genomes of NAFLD patients and possible genetic determinants of therapeutic responses should also be explored to develop more personalized therapies.

**REFERENCES**

1. Trovato FM, Martines GF, Catalano D, Musumeci G, Pirri C, Trovato GM. Echocardiography and NAFLD (non-alcoholic fatty liver disease). *Int J Cardiol* 2016; 221: 275-279 [PMID: 27404689 DOI: 10.1016/j.ijcard.2016.06.190]
2. Trovato FM, Castrogiovanni P, Szychlinska MA, Purrello F, Musumeci G. Early effects of high-fat diet, extra-virgin olive oil and vitamin D in a sedentary rat model of non-alcoholic fatty liver disease. *Histol Histopathol* 2018; 33: 1201-1213 [PMID: 29885033 DOI: 10.14470/HH-18-008]
3. Trovato FM, Martines GF, Brischetto D, Catalano D, Musumeci G, Trovato GM. Fatty liver disease and lifestyle in youngers: diet, food intake frequency, exercise, sleep shortage and fashion. *Liver Int* 2016; 36: 427-433 [PMID: 26344413 DOI: 10.1111/liv.12957]
4. Cholankeril G, Patel R, Khrura S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. *World J Hepatol* 2017; 9: 533-543 [PMID: 28469909 DOI: 10.4254/wjh.v9.i11.533]
5. Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. *World J Hepatol* 2017; 9: 715-732 [PMID: 28652891 DOI: 10.4254/wjh.v9.i16.715]
6. Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. *Expert Rev Gastroenterol Hepatol* 2019; 13: 193-204 [PMID: 30791767 DOI: 10.1080/17474124.2019.1569513]
7. Trovato FM, Catalano D, Musumeci G, Trovato GM. 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. *EPMA J* 2014; 5: 21 [PMID: 25937854 DOI: 10.1186/1878-5085-5-21]
8. Trovato FM, Castrogiovanni P, Malatino L, Musumeci G. Nonalcoholic fatty liver disease (NAFLD) prevention: role of Mediterranean diet and physical activity. *Hepatobiliary Surg Nutr* 2019; 8: 167-169 [PMID: 31098570 DOI: 10.21037/hbsn.2018.12.05]
9. Wong VW, Singal AK. Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis. *Transl Gastroenterol Hepatol* 2019; 4: 53 [PMID: 31463412 DOI: 10.21037/gh.2019.06.06]
10. Han R, Ma J, Li H. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. *Front Med* 2018; 12: 645-657 [PMID: 30178233 DOI: 10.1007/s11684-018-0645-9]
11. Ding Y, Yanagi K, Cheng C, Alaniz RC, Lee K, Jayaraman A. Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites. *Pharmacol Res* 2019; 141: 521-529 [PMID: 30660825 DOI: 10.1016/j.phrs.2019.01.029]
12. Zhou D, Fan JG. Microbial metabolites in non-alcoholic fatty liver disease. *World J Gastroenterol* 2019; 25: 2019-2028 [PMID: 31114130 DOI: 10.3748/wjg.v25.i17.2019]
Clostridium butyricum MIYAIRI 588 improves high-fat diet-induced non-alcoholic fatty liver disease in rats, Inoue I, Tanaka M, Matsuda N, Nakano T, Awata T, Katayama S, Alpers DH, Komoda T. 8 PLoS One 2013; 8: e51582 DOI: 10.1371/journal.pone.0051582

Arendt BM, Ma DW, Simons B, Noureddin SA, Therapondos G, Guindi M, Sherman M, Allard JP. Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine. Appl Physiol Nutr Metab 2013; 38: 334-340 PMID: 23537027 DOI: 10.1139/apnm-2012-0261

Chu H, Duan Y, Yang L, Schnabl B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut 2019; 68: 359-370 PMID: 30171065 DOI: 10.1136/gutjnl-2018-313607

Arab JP, Karpem SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology 2017; 65: 350-362 PMID: 27358174 DOI: 10.1002/hep.28709

Winston JA, Thriot CM. Diversification of host bile acids by members of the gut microbiota. Gut Microbes 2020; 11: 158-171 PMID: 31595814 DOI: 10.1080/19490976.2017.1547243

Suzumura K, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 2018; 53: 362-376 PMID: 29247356 DOI: 10.1007/s00535-017-1415-1

Cho MS, Kim SY, Suk KT, Kim BY. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol 2018; 56: 855-867 PMID: 30377993 DOI: 10.1007/s12277-018-8346-2

Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausk W, Cai J, Qi Y, Fang ZZ, Takahashi S, Tanaka N, Desai D, Amin SG, Albert I, Patterson AD, Gonzalez FJ. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015; 125: 386-402 PMID: 25500885 DOI: 10.1172/JCI76738

Ma J, Zhou Q, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients 2017; 9: 29035308 DOI: 10.3390/nu9011024

Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tushu KM, Thomas LV, Zoetendal EG, Hart A. The gut microbiota and host health: a new clinical frontier. Gut 2016; 65: 330-339 PMID: 26338272 DOI: 10.1136/gutjnl-2015-309990

Safari Z, Girard P. The links between gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 2019; 76: 1541-1558 PMID: 30683985 DOI: 10.1007/s00018-019-03011-w

Sidhu M, van der Poorten D. The gut microbiome. Aust Fam Physician 2017; 46: 206-211 PMID: 28376573

Dawson AM, McLaren J, Sherlock S. Neomycin in the treatment of hepatic coma. Lancet 1957; 273: 1262-1268 PMID: 13492621

Sharma P, Sharma BC. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 2423-2424 author reply 2424-2425 PMID: 20578274

Bergeim I, Weber S, Mos M, Krämer S, Volyvenets V, Kaserouni S, McClain CJ, Bischoff SC. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2010; 53: 815-821 PMID: 20038768 DOI: 10.1016/j.jhep.2010.04.003

Eldeeb AA, Awad M, Elgamal A, Attia A, El-Wakeel N, Eldars W. Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot. J Microbiol 2017; 23: 840-845 PMID: 26043290 DOI: 10.1007/MEG.00000000000000348

Aldel-Razik A, Moussa N, Shabana W, Refaey M, Elzehery R, Elhelaly R, Zalata K, Abdelsalam M, Mousa N. Rifaximin treatment in hepatic encephalopathy. Gastroenterol Hepatol 2018; 33: 108-119 PMID: 29530742 DOI: 10.1097/MEG.0000000000001232

Gangarapu V, Ince AT, Baysal B, Kayar Y, Kılıç U, Gök Ö, Uysal Ö, Şenturk H. Efficacy of rifaximin in the treatment of hepatic encephalopathy. World J Gastroenterol 2013; 19: 7680-7686 PMID: 23964028 DOI: 10.3748/wjg.v19.i25.7680

Yu Y, Farris AB, Nusrat A, Parkos CA, Anania FA. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. Gastroenterology 2016; 151: 733-746.e12 PMID: 27342212 DOI: 10.1053/j.gastro.2016.06.022

Loomba R, Seguritan V, Li W, Long T, Kiltograd N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highland SK, Jones MB, Sirlin CB, Schnabl B, Brunkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab 2019; 30: 607 PMID: 31484056 DOI: 10.1016/j.cmet.2019.09.002

Mouzaki M, Wang HY, Bandama R, Comelli EM, Arendt BM, Zhang L, Fang S, Fischer SE, McGilvery IG, Allard JP. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. PLoS One 2016; 11: e0151829 PMID: 27200308 DOI: 10.1371/journal.pone.0151829

Marchesi JR, Alpers DH, Ince AT, Baysal B, Kayar Y, Kılıç U, Gök Ö, Uysal Ö, Şenturk H. Efficacy of rifaximin in the treatment of hepatic encephalopathy. Aust Fam Physician 2017; 46: 206-211 PMID: 28376573
Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. *Aliment Pharmacol Ther* 2012; 36: 503-516 [PMID: 22827693 DOI: 10.1111/j.1365-2036.2012.05220.x]

Cai TT, Ye XL, Yong HJ, Song H, Zheng XL, Cui BT, Zhang FM, Lu YB, Miao H, Ding DF. Fecal microbiota transplantation relieves painful diabetic neuropathy: A case report. *Medicine (Baltimore)* 2018; 97: e13543 [PMID: 30558014 DOI: 10.1097/MD.00000000000013543]

de Groot P, Scheithauer T, Bakker GJ, Prodan A, Levin E, Khan MT, Herrema H, Ackermans M, Serlie MJM, de Brouw M, Levendahl JM, Sales A, Gerdes VE, Stählin M, Schimmel AW, Dalila-Thie G, Bergman JJ, Holleman F, Hodicka JHL, Groen A, Bäckhed F, Nieuwdorp M. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. *Gut* 2020; 69: 502-512 [PMID: 31147381 DOI: 10.1136/gutjnl-2019-31820]

He Z, Cui BT, Zhang T, Li P, Long CY, Ji GZ, Zhang FM. Fecal microbiota transplantation cured epilepsy in a case with Crohn's disease: The first report. *World J Gastroenterol* 2017; 23: 3565-3568 [PMID: 28596693 DOI: 10.3748/wjg.v23.i23.3565]

Kooste RS, Levin E, Saljärvi J, Smits LP, Hartstra AV, Udayappan SD, Hermes G, Boutier KE, Koopen AM, Holst JJ, Knop FK, Blaak EE, Zhao J, Smith H, Harms AC, Hankemeijer T, Bergman JGJHM, Romijn HA, Schaap FG, Olde Dambink SWM, Ackermans MT, Dalila-Thie GM, Zoetendal E, de Vos WM, Serlie MJ, Stroes ESG, Groen AK, Nieuwdorp M. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. *Cell Metab* 2017; 26: 611-619.e6 [PMID: 28978426 DOI: 10.1016/j.cmet.2017.09.008]

Le Roy T, Llopis M, Lepeau P, Bruneau A, Rabot S, Bevlacqua C, Martin P, Philippe C, Walker F, Bado A, Perlemuter G, Cassard-Doulair AM, Gérard P. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. *Gut* 2013; 62: 1787-1794 [PMID: 23197411 DOI: 10.1136/gutjnl-2012-303816]

Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YYW, Fan JG. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. *Sci Rep* 2017; 7: 1529 [PMID: 28484237 DOI: 10.1038/s41598-017-01715-y]

Bajaj JS, Fagan A, Sikaroudi M, White MB, Sterling RK, Gilles H, Heuman D, Stravitz RT, Matherly SC, Siddiqui MS, Puri P, Sanyal AJ, Luketic V, John B, Fuchs M, Ahluwalia V, Gillevei PM. Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. *Liver Transpl* 2017; 23: 907-914 [PMID: 28240840 DOI: 10.1002/lt.24754]

Moustyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinsch W, Lee CH. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. *Gastroenterology* 2015; 149: 102-109.e6 [PMID: 25857665 DOI: 10.1053/j.gastro.2014.05.001]

Brestoff JR, Artis D. Commensal bacteria at the interface of host metabolism and the immune system. *Nat Immunol* 2013; 14: 676-684 [PMID: 23778795 DOI: 10.1038/nii.2640]

Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, Tuohy K. Gut microbiota functions: metabolism of nutrients and other food components. *Eur J Nutr* 2018; 57: 1-24 [PMID: 28393285 DOI: 10.1007/s00394-017-1445-8]

Ahmad TR, Haeusler RA. Bile acids in glucose metabolism and insulin signalling - mechanisms and research needs. *Nat Rev Endocrinol* 2019; 15: 701-712 [PMID: 31616073 DOI: 10.1038/s41574-019-0266-7]

Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. *Cell* 2016; 165: 1332-1345 [PMID: 27259147 DOI: 10.1016/j.cell.2016.05.041]

Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. *Nat Rev Immunol* 2016; 16: 341-352 [PMID: 27231050 DOI: 10.1038/nri.2016.42]

Levy M, Blacher E, Elinav E. Microbiome, metabolites, and host immunity. *Curr Opin Microbiol* 2017; 35: 8-15 [PMID: 27883937 DOI: 10.1016/j.mib.2016.10.003]

Lin L, Zhang J. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases. *BMC Immunol* 2018; 18: 2 [PMID: 28061847 DOI: 10.1186/s12865-016-0187-3]

Lustri BC, Sperandio V, Moreira CG. Bacterial Chat: Intestinal Metabolites and Signals in Host-Microbiota-Pathogen Interactions. *Infect Immun* 2017; 85: 26947641 DOI: 10.1128/IAI.00476-17]

Soes J, Elinav E. The path towards microbiome-based metabolic treatment. *Nat Microbiol* 2017; 2: 17075 [PMID: 28540921 DOI: 10.1038/s41561-017-0266-7]

McIntyre A, Gibson PR, Young GP. Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. *Gut* 1993; 34: 386-391 [PMID: 8386131 DOI: 10.1136/gut.34.3.386]

Hinnebusch BF, Mithieux G. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. *Cell* 2014; 156: 84-96 [PMID: 24412651 DOI: 10.1016/j.cell.2013.12.016]

Donohoe DR, Garge N, Zhang X, Sun W, O’Connell TM, Bunger MK, Bultman SJ. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. *Cell Metab* 2011; 13: 517-526 [PMID: 21531334 DOI: 10.1016/j.cmet.2011.02.018]

Round JL, Mazmanian SK. Inducible Fsp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. *Proc Natl Acad Sci USA* 2010; 107: 12204-12209 [PMID: 20566854 DOI: 10.1073/pnas.0909122107]

Atarashi K, Tanoue T, Shinma T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov I, Umesaki Y, Itoh K, Honda K. Induction of colonic regulatory T cells by indigenous Clostridium species. *Science* 2011; 331: 337-341 [PMID: 21205640 DOI: 10.1126/science.1205640]
Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science* 2013; 341: 569-573 [PMID: 23828893 DOI: 10.1126/science.1241165]

Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG. Minireview: Gut microbiota: the neglected endocrine organ. *Mol Endocrinol* 2014; 28: 1221-1238 [PMID: 24892638 DOI: 10.1210/me.2014-1108]

Kim H, Fang S. Crosstalk between FXR and TGR5 controls glucagon-like peptide 1 secretion to maintain glycemic homeostasis. *Lab Anim Res* 2018; 34: 140-146 [PMID: 30671099 DOI: 10.5625/lar.2018.34.4.140]

Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, Li T, Yin Y. Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism. *Front Cell Infect Microbiol* 2018; 8: 13 [PMID: 29468141 DOI: 10.3389/fcimb.2018.00013]

Robinson MW, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. *Cell Mol Immunol* 2016; 13: 267-276 [PMID: 27063467 DOI: 10.1038/cmi.2016.3]
